Richard Wyatt | Professor, Department of Immunology and Microbiology
The Scripps Research Institute

Richard Wyatt, Professor, Department of Immunology and Microbiology, The Scripps Research Institute

Richard T Wyatt, Ph.D., received his Doctorate in Immunology from Tufts University School of Graduate Biomedical Sciences in Boston, MA and did his postdoctoral training at the Harvard School of Medicine. Currently, Dr. Wyatt is a tenured Professor in the Department of Immunology and Microbiology at the Scripps Research Institute in La Jolla, CA. Dr. Wyatt has served on the editorial board of the Journal of Virology, is a member of the Scripps CHAVD, the IAVI Neutralizing Antibody Consortium at Scripps, the UCSD CFAR Executive and Grant Review Committees, the American Foundation for AIDS Research Cure Working Group and the American Association for the Advancement of Science. He has co-authored over 160 peer-reviewed articles, predominantly focused on the HIV-1 envelope glycoproteins (Env) as antigens and immunogens, and has been listed on the Thomson-Reuters World’s Most Influential Scientific Minds and Highly Cited Researchers for multiple years. Prior to Scripps, Dr. Wyatt was a tenured Senior Investigator and Chief of the Structural Immunology at the Vaccine Research Center at the NIH. Dr. Wyatt’s research focuses on the structure, function and especially the immunogenicity of the HIV-1 Env, the only virally encoded protein on the surface of the virus. Dr. Wyatt’s lab has developed structure-guided HIV-1 Env trimers to be used as candidate vaccines to elicit antibodies directed against the glycan-shielded cross-neutralizing determinants. His lab engineers a diverse array of near-native, homogeneous trimers to generate HIV broadly neutralizing antibodies (bNAbs) in preclinical models similar to those elicited during natural infection. Dr. Wyatt’s laboratory is one of the few that elicits cross-neutralizing antibodies in preclinical animal models following vaccination of engineered HIV Env trimers toward HIV -1 vaccine development. The Wyatt group is also exploring the use of bNAbs for HIV-1 curative modalities.  


WVIC/WAC Day 2 - Nov 30 @ 15:00

Pre-clinical evaluation of HIV envelope glycoprotein vaccine candidates towards the clinic

last published: 01/Dec/22 17:25 GMT

back to speakers

For conference programme and speaking opportunities:
Lauren Sheppard

For sponsorship and exhibition opportunities:
Thomas Hall